Annexon, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Annexon, Inc. (ANNX) on August 10, 2026. The filing discloses changes to the composition of the Board of Directors, specifically the resignation of a long-serving director and the appointment of a new director with expertise in retinal surgery and biotechnology.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Resignation: Muneer Satter resigned from the Board, the Audit Committee, and as Chair of the Nominating and Corporate Governance Committee, effective immediately prior to the appointment of his replacement. The resignation was not due to any disagreement with the Company regarding operations, policies, or strategy.
- Director Appointment: Mark S. Blumenkranz, M.D., M.S.S., was appointed to the Board as a Class II director, with a term expiring at the 2028 annual meeting. He was also appointed to the Audit Committee and the Science and Technology Committee.
Compensation and Governance Details
Dr. Blumenkranz's compensation under the Non-Employee Director Compensation Program includes:
- An annual retainer of $40,000.
- An initial stock option grant to purchase 175,000 shares of common stock under the 2020 Incentive Award Plan, granted on the effective date in lieu of the standard automatic initial grant.
- Future automatic grants of stock options to purchase 65,000 shares on the date of each annual stockholder meeting, vesting on the earlier of the first anniversary of the grant or the next annual meeting.
Dr. Blumenkranz has also entered into the Company's standard indemnification and advancement agreement for directors.
Investor Verification Checklist
- Verify the biographical background and potential conflicts of interest for the new director, Dr. Mark S. Blumenkranz.
- Review the Company's 2020 Incentive Award Plan to understand the terms of the 175,000 share option grant.
- Confirm the status of the Audit Committee and Nominating Committee following the transition of leadership.
- Check for any subsequent filings regarding the departure of Mr. Satter or the onboarding of Dr. Blumenkranz.